keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/28646440/a-comparison-of-three-different-intravitreal-treatment-modalities-of-macular-edema-due-to-branch-retinal-vein-occlusion
#1
Havva Erdogan Kaldırım, Serpil Yazgan
PURPOSE: To compare the efficacy of intravitreal injection of ranibizumab, dexamethasone implant and aflibercept for the management of macular edema (ME) related to branch retinal vein occlusion (BRVO). METHODS: This retrospective and comparative study included 62 eyes of 62 patients with BRVO and ME. Patients received one of the following treatments: 0.5 mg ranibizumab (group 1, n = 22), 0.7 mg dexamethasone implant (group 2, n = 20) and 2 mg aflibercept (group 3, n = 20)...
June 23, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28642823/visualization-of-changes-in-the-foveal-avascular-zone-in-both-observed-and-treated-diabetic-macular-edema-using-optical-coherence-tomography-angiography
#2
Aditya Gill, Emily D Cole, Eduardo A Novais, Ricardo N Louzada, Talisa de Carlo, Jay S Duker, Nadia K Waheed, Caroline R Baumal, Andre J Witkin
BACKGROUND: Central vision loss in diabetic retinopathy is commonly related to diabetic macular edema (DME). The objective of this study was to describe changes between consecutive visits on optical coherence tomography angiography (OCTA) of the foveal avascular zone (FAZ) in eyes with DME. METHODS: 20 eyes from 14 patients with DME were imaged on 2 successive clinic visits separated by at least 1 month. The mean interval between visits was 3.2 months. The only intervention used was intravitreal anti-VEGF in 11 eyes; the others were observed over time without treatment...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28641290/long-term-follow-up-of-choroidal-neovascularization-due-to-angioid-streaks-with-pro-re-nata-intravitreal-anti-vegf-treatment
#3
Giovanni Giacomelli, Lucia Finocchio, Ilaria Biagini, Andrea Sodi, Vittoria Murro, Ugo Introini, Monica Varano, Francesco Bandello, Ugo Menchini
PURPOSE: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) drugs with a pro re nata (PRN) regimen for the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). METHODS: This is a retrospective, multicenter, noncomparative case series of consecutive AS eyes affected by treatment-naïve CNV. A complete ophthalmologic examination was performed every 30-45 days after the loading phase, including fluorescein angiography and/or optical coherence tomography...
June 23, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28639415/anti-vascular-endothelial-growth-factor-for-diabetic-macular-oedema-a-network-meta-analysis
#4
REVIEW
Gianni Virgili, Mariacristina Parravano, Jennifer R Evans, Iris Gordon, Ersilia Lucenteforte
BACKGROUND: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities can reduce oedema and thereby improve vision and prevent further visual loss. These drugs have replaced laser photocoagulation as the standard of care for people with DMO. OBJECTIVES: The 2014 update of this review found high-quality evidence of benefit with antiangiogenic therapy with anti-VEGF modalities, compared to laser photocoagulation, for the treatment of DMO...
June 22, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28639290/comparison-between-anti-vegf-therapy-and-corticosteroid-or-laser-therapy-for-macular-oedema-secondary-to-retinal-vein-occlusion-a-meta-analysis
#5
REVIEW
T Qian, M Zhao, X Xu
WHAT IS KNOWN AND OBJECTIVE: Therapeutic effects of anti-VEGF agents, corticosteroids and laser therapy have been previously examined for treating macular oedema secondary to branch and central retinal vein occlusion (BRVO and CRVO). However, anti-VEGF efficacy has not been previously compared to corticosteroid or laser therapy efficacy. We performed a meta-analysis to compare these treatments. METHODS: Pertinent publications were identified through comprehensive literature searches...
June 22, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28630947/evolution-of-geographic-atrophy-in-participants-treated-with-ranibizumab-for-neovascular-age-related-macular-degeneration
#6
Alisa T Thavikulwat, Naima Jacobs-El, Jane S Kim, Elvira Agrón, Jesia Hasan, Catherine B Meyerle, David Valent, Catherine A Cukras, Henry E Wiley, Wai T Wong, Emily Y Chew
PURPOSE: To evaluate the risk factors, incidence, and rate of progression of geographic atrophy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ranibizumab. DESIGN: Post-hoc analysis of a prospective clinical study. PARTICIPANTS: 69 participants with nAMD in at least one eye. METHODS: Participants were prospectively treated in the study eye with 0.5 mg intravitreal ranibizumab. Study eyes received 4 monthly injections followed by pro re nata injections until a fluid-free macula was achieved on optical coherence tomography...
January 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28620652/visual-and-morphologic-outcomes-in-eyes-with-hard-exudate-in-the-comparison-of-age-related-macular-degeneration-treatments-trials
#7
Ebenezer Daniel, Juan E Grunwald, Benjamin J Kim, Maureen G Maguire, Glenn J Jaffe, Cynthia A Toth, Frederick L Ferris, Daniel F Martin, James Shaffer, Gui-Shuang Ying
PURPOSE: To compare baseline characteristics, visual acuity (VA) and morphological outcomes between eyes with baseline hard exudates (HE) and all other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with anti-vascular endothelial growth factors (anti-VEGF). DESIGN: Prospective cohort study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). PARTICIPANTS: Patients with NVAMD...
January 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28598120/-characteristics-and-clinical-significance-of-outer-retinal-tubulation-in-wet-age-macular-degeneration-treated-by-anti-vascular-endothelial-growth-factor-through-optical-coherence-tomography
#8
Cheng Zuo, Xun Li, Zi-Rong Zhang, Mei-Xia Zhang
OBJECTIVES: To determine the characteristics and clinical significance of outer retinal tabulation (ORT) in wet age-related macular degeneration (wAMD) treated by anti-vascular endothelial growth factor (anti-VEGF) through optical coherence tomography (OCT). METHODS: The 35 wAMD patients with 39 ORT eyes treated by anti-VEGF were examined by OCT to determine the morphological features and evolution of the ORTs over time and their response to anti-VEGF. RESULTS: ORTs were located in the places that exudation or edema had happened in the outer nuclear layer of retina...
November 2016: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/28592811/evaluating-the-impact-of-vitreomacular-adhesion-on-anti-vegf-therapy-for-retinal-vein-occlusion-using-machine-learning
#9
Sebastian M Waldstein, Alessio Montuoro, Dominika Podkowinski, Ana-Maria Philip, Bianca S Gerendas, Hrvoje Bogunovic, Ursula Schmidt-Erfurth
Vitreomacular adhesion (VMA) represents a prognostic biomarker in the management of exudative macular disease using anti-vascular endothelial growth factor (VEGF) agents. However, manual evaluation of VMA in 3D optical coherence tomography (OCT) is laborious and data on its impact on therapy of retinal vein occlusion (RVO) are limited. The aim of this study was to (1) develop a fully automated segmentation algorithm for the posterior vitreous boundary and (2) to study the effect of VMA on anti-VEGF therapy for RVO...
June 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28570723/oral-tyrosine-kinase-inhibitor-for-neovascular-age-related-macular-degeneration-a-phase-1-dose-escalation-study
#10
Timothy L Jackson, David Boyer, David M Brown, Nauman Chaudhry, Michael Elman, Chris Liang, Denis O'Shaughnessy, Edward C Parsons, Sunil Patel, Jason S Slakter, Philip J Rosenfeld
Importance: An oral treatment for neovascular age-related macular degeneration would be less burdensome than repeated intravitreous injections. X-82 is an oral tyrosine kinase inhibitor active against vascular endothelial growth factor (VEGF) and platelet-derived growth factor. Objective: To undertake safety testing of oral X-82 administered for the treatment of neovascular AMD. Design, Setting, and Participants: Phase 1, open-label, uncontrolled, dose-escalation study at 5 US retinal clinics between November 2012 and March 2015 (Retina-Vitreous Associates Medical Group, Beverly Hills, California; Blanton Eye Institute, Houston Methodist Hospital, Retina Consultants of Houston, Houston, Texas; New England Retina Associates, Guilford, Connecticut; Elman Retina Group, Baltimore, Maryland; and Retina Research Institute of Texas, Abilene)...
June 1, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28564655/aqueous-humor-levels-of-soluble-vascular-endothelial-growth-factor-receptor-and-inflammatory-factors-in-diabetic-macular-edema
#11
Hidetaka Noma, Tatsuya Mimura, Kanako Yasuda, Ryosuke Motohashi, Osamu Kotake, Masahiko Shimura
Aqueous levels of soluble vascular endothelial growth factor receptor (sVEGFR) and inflammatory factors were measured in 35 patients (37 eyes) with diabetic macular edema (DME) receiving anti-vascular endothelial growth factor (VEGF) therapy. Aqueous levels of growth factors (VEGF, placental growth factor [PlGF], and platelet-derived growth factor AA [PDGF-AA]), sVEGFR-1 and -2, soluble intercellular adhesion molecule 1, monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, -8, -12, and -13, and interferon-inducible 10-kDa protein (IP-10) were significantly higher in the DME group than in the nondiabetic control group...
June 1, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28557667/real-life-experience-with-aflibercept-and-ranibizumab-in-the-treatment-of-newly-diagnosed-neovascular-age-related-macular-degeneration-over-24-months
#12
Justus G Garweg, Christin Gerhardt, Laurent Kodjikian, Isabel B Pfister
PURPOSE: Comparative data appertaining to the long-term effects of Aflibercept or Ranibizumab in newly diagnosed cases of neovascular age-related macular degeneration (nAMD) over follow-up periods exceeding 12 months in clinical routine are scarce. METHODS: In this retrospective comparative analysis, a case series of patients with treatment-naïve nAMD and requiring anti-vascular endothelial growth factor (VEGF) therapy in a routine clinical setting were treated with either Aflibercept [Afl (n = 106)] or Ranibizumab [Ran (n = 47)]...
May 30, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28557571/in-vivo-efficacy-of-an-injectable-microsphere-hydrogel-ocular-drug-delivery-system
#13
Christian R Osswald, Micah J Guthrie, Abigail Avila, Joseph A Valio, William F Mieler, Jennifer J Kang-Mieler
PURPOSE: Demonstrate in vivo that controlled and extended release of a low dose of anti-vascular endothelial growth factor (anti-VEGF) from a microsphere-hydrogel drug delivery system (DDS) has a therapeutic effect in a laser-induced rat model of choroidal neovascularization (CNV). METHODS: Anti-VEGF (ranibizumab or aflibercept) was loaded into poly(lactic-co-glycolic acid) microspheres that were then suspended within an injectable poly(N-isopropylacrylamide)-based thermo-responsive hydrogel DDS...
May 30, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28553669/simultaneous-dexamethasone-intravitreal-implant-and-anti-vegf-therapy-for-neovascular-age-related-macular-degeneration-resistant-to-anti-vegf-monotherapy
#14
Bozho Todorich, Aristomenis Thanos, Yoshihiro Yonekawa, Gerta Mane, Madeleine Hasbrook, Benjamin J Thomas, Maria A Woodward, George A Williams, Antonio Capone, Jeremy D Wolfe, Lisa J Faia, Tarek S Hassan
PURPOSE: To evaluate the efficacy of a dexamethasone intravitreal implant in combination with intravitreal anti-VEGF agents for treatment resistant neovascular age-related macular degeneration (nvAMD). METHODS: This study was designed as a single-center, retrospective interventional case series. Consecutive patients with treatment-resistant nvAMD underwent simultaneous combined injection of anti-VEGF agent and dexamethasone intravitreal implant. Eighteen patients with mean age of 81...
2017: J Vitreoretin Dis
https://www.readbyqxmd.com/read/28551897/-phacoemulsification-in-eyes-with-neovascular-age-related-macular-degeneration-amd
#15
Daniel Rappoport, Mordechai Goldberg, Amir Bukelman, Haya Katz, Lital Goldberg, Ayala Pollack
INTRODUCTION: Age-related macular degeneration (AMD) is the leading cause of blindness in the western world. The debate continues over the safety of cataract surgery in the setting of neovascular (wet) AMD. This retrospective review aims to describe our experience in treating patients with wet AMD, who underwent cataract surgery by phacoemulsification. METHODS: We prepared a retrospective chart review of patients treated in our clinic between the years 2006 - 2013...
February 2017: Harefuah
https://www.readbyqxmd.com/read/28548650/aflibercept-in-age-related-macular-degeneration-evaluating-its-role-as-a-primary-therapeutic-option
#16
REVIEW
M Ashraf, A A R Souka
The recent VIEW studies have demonstrated the non-inferiority of monthly and bi-monthly aflibercept in the management of wet age related macular degeneration (AMD) compared with ranibizumab. However, the current data are limited mainly to fixed dosing regimens with few studies looking at flexible dosing regimens of aflibercept in wet AMD. In addition, recent data from the VIEW 96 week extension has shown that patients being shifted from fixed dosing regimens to PRN have shown a drop in visual acuity and increase in central macular thickness...
May 26, 2017: Eye
https://www.readbyqxmd.com/read/28547797/vitamin-d-receptor-agonists-regulate-ocular-developmental-angiogenesis-and-modulate-expression-of-dre-mir-21-and-vegf
#17
Stephanie L Merrigan, Breandán N Kennedy
BACKGROUND AND PURPOSE: Pathological growth of ocular vasculature networks can underpin visual impairment in neovascular age-related macular degeneration, proliferative diabetic retinopathy and retinopathy of prematurity. Our aim was to uncover novel pharmacological regulators of ocular angiogenesis by phenotype-based screening in zebrafish. EXPERIMENTAL APPROACH: A bioactive chemical library of 465 drugs was screened to identify small molecule inhibitors of ocular hyaloid vasculature (HV) angiogenesis in zebrafish larvae...
May 26, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28546934/foveal-thickness-reduction-after-anti-vascular-endothelial-growth-factor-treatment-in-chronic-diabetic-macular-edema
#18
Gabriel Willmann, Antonio Brunno Nepomuceno, Katharina Messias, Leticia Barroso, Ingrid U Scott, André Messias, Rodrigo Jorge
AIM: To report foveal thickness reduction in eyes with resolution of macular edema and recovery of a foveal depression after one-year of anti-vascular endothelial growth factor (anti-VEGF) therapy for center-involving diabetic macular edema (DME). METHODS: Foveal thickness was assessed with optical coherence tomography to determine the central subfield foveal thickness (CSFT) and macular volume in 42 eyes with DME (CSFT>275 µm). Evaluations also included measurement of best-corrected visual acuity (BCVA), and were performed at baseline, and upon foveal depression recovery achieved after 12 monthly intravitreal injections of either 1...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28546150/six-year-outcomes-of-antivascular-endothelial-growth-factor-monotherapy-for-polypoidal-choroidal-vasculopathy
#19
Taiichi Hikichi
OBJECTIVE: To evaluate the 6-year outcomes of anti-VEGF (vascular endothelial growth factor) monotherapy for polypoidal choroidal vasculopathy (PCV). METHODS: The charts of 66 eyes of 66 patients with newly diagnosed, symptomatic, treatment-naive PCV were reviewed retrospectively. All patients were treated with 0.5 mg intravitreal ranibizumab (IVR) injections for 3 months followed by as-needed reinjections based on monthly examinations until 3 years after the first IVR injection...
May 25, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28541266/retinochoroidal-anastomosis-associated-with-enhanced-s-cone-syndrome
#20
Jennyfer Zerbib, Rocio Blanco Garavito, Sylvie Gerber, Hassiba Oubraham, Anne Sikorav, Isabelle Audo, Josseline Kaplan, Jean-Michel Rozet, Eric H Souied
PURPOSE: To describe the phenotype and genotype of a 10-year-old boy affected with enhanced S-cone syndrome associated with neovascularization. METHODS: Fundus autofluorescence, fluorescein angiography, indocyanine green angiography, spectral domain optical coherence tomography, full-field electroretinogram and NR2E3 molecular testing were performed. RESULTS: Best-corrected visual acuity was measured as 20/32, right eye and 20/20, left eye...
May 22, 2017: Retinal Cases & Brief Reports
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"